Idexx Laboratories (IDXX)
Health Care · veterinary diagnostics · NASDAQ
IDEXX Laboratories is a global pet healthcare leader providing essential diagnostic, laboratory, and software solutions to veterinary practitioners worldwide.
What Idexx Laboratories does
IDEXX Laboratories is a global leader in pet healthcare innovation, providing diagnostic and software solutions for veterinary practitioners. The company offers a broad range of diagnostic instruments, test kits, and reference laboratory services, alongside practice management software, to help veterinarians provide advanced medical care and improve practice efficiency.
Themes: pet healthcare, veterinary diagnostics, animal health software, medical diagnostics
Fundamentals
- Price$513.14 as of 2026-10-08 close
- Market cap$40.4B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-18.5% 2025-10-08 close $629.91 → 2026-10-08 close $513.14
- P/E36.07 as of 2026-10-08
- Net margin+24.6% FY2025, SEC XBRL
- Gross margin+61.8% FY2025, SEC XBRL
- ROE+66.0% FY2025, SEC XBRL
- Debt / equity0.60 as of 2026-09-03
- Revenue growth (YoY)+12.8% as of 2026-09-03
- Revenue CAGR (3y)+8.5% SEC XBRL
- Beta0.94 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How IDXX compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IDXX is not currently in any published Top 10 list. Its scores are below.
Top 10 score
53.9 #527 of 1,379 scored · #63 of 151 in Health Care
Profitability 93rd (return on equity 66%, operating margin 31.6%) and financial health 67th (free cash flow margin 24.6%, debt to equity 0.6); weakest is valuation (22nd, price to book 25.1, price to earnings 36.1).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Idexx Laboratories looks technically
Idexx Laboratories (IDXX) is trading 12.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 133 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 20 trading days ago. It is 2.5% above its 52-week low (its lowest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 12.5% below its 200-day average, the long-term trend line — a long-term downtrend | -12.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $540.25 | $540.25 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $586.27 | $586.27 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 536.84. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 133 trading days ago — a "death cross", a bearish long-term signal | 133 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 44.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($501.17 to $536.84) — its "stochastic" reading is 34 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 33.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $769.98 | $769.98 |
|---|---|---|
| From the 52-week high | it is 33.4% below its 52-week high (its highest price of the past year) | -33.4% |
| Above the 52-week low | it is 2.5% above its 52-week low (its lowest price of the past year) | +2.5% |
| Below the 52-week high | it is 33.4% below its highest point of the past year | 33.4% |
| Since a 20-day breakout | it made a new 20-day low about 20 trading days ago | 20 sessions |
| Since a 55-day breakout | it made a new 55-day low about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $769.98 (set on 2025-11-26) | $769.98 |
| Given back of the 52-week move | over the past year its closes ranged ($504.70 to $766.68), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $666.60 to $674.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.2% |
| From the all-time high | it is 33.4% below its all-time high | -33.4% |
| Nearest price level | it is trading 0.5% above a support level at $510.42 — a price it turned at twice since 2025-06-17, most recently on 2025-07-16. Since 2024-10-08 it has 6 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $12.05 (set on 2008-10-24) | $12.05 |
| Above the all-time low | it is 4156.7% above its all-time low | +4,157% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move | 5th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $13.06 between its high and its low — about 2.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $13.06 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $501.53 and $531.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $501.53 – $516.57 – $531.60 |
| Typical daily range (% of price) | its price moves about 2.5% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.5% |
| Stretch from the 200-day average | it is trading 5.6 daily ranges below its 200-day average price (12.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.40× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.3% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.06 toward buy |
Candlestick patterns
2
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 6.4% gap up opened on 2026-08-04 has been "filled" 39 sessions ago — price traded back through the level the gap left behind, and it took 7 sessions to close | 39 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.4 percentage points (the stock lost 1.4% while the market gained 1.0%) | -2.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 11.5 percentage points (the stock lost 7.7% while the market gained 3.8%) | -11.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 28.6 percentage points (the stock lost 11.1% while the market gained 17.5%) | -28.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 33.5 percentage points (the stock lost 18.5% while the market gained 15.0%) | -33.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.9% of the share price, which is taken to mean a barrier that gives way easily. | -9.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $578.51 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -11.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $541.83 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -5.3% |
Price levels it has turned at before
IDXX last closed at $513.14 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $510.42 | Support | 0.5% below the last close | turned there twice · 2025-06-17 to 2025-07-16 |
| $524.79 | Resistance | 2.3% above the last close | turned there five times · 2025-05-20 to 2026-06-30 |
| $498.61 | Support | 2.8% below the last close | turned there twice · 2025-05-23 to 2026-09-11 |
| $537.91 | Resistance | 4.8% above the last close | turned there five times · 2026-04-29 to 2026-09-29 |
| $548.53 | Resistance | 6.9% above the last close | turned there three times · 2025-07-07 to 2026-06-03 |
| $450.55 | Support | 12.2% below the last close | turned there twice · 2024-10-21 to 2024-12-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $536.84.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $336.95 and $413.30 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $536.84.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Near the 52-week low · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.15 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$701.33 range $470.00 – $805.00; median $705.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IDXX
- Consensus EPS estimate$3.70 next reporting period, as of 2026-10-09
- Estimate change, 30 days-$0.00456 (-0.1%) from $3.71, on 2026-09-04, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the veterinary diagnostic market and the volume of veterinary visits.","Significant exposure to risks associated with international operations and foreign currency exchange rate fluctuations.","Competition from established healthcare diagnostic companies and consolidators in the veterinary industry."]
What changed in the latest 10-Q
AI-assisted comparison of IDXX's 10-Q filed 2026-05-05 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05) added explicit reference to '2025 Annual Report' instead of '2024 Annual Report'
- Newer filing (2026-05-05) changed fiscal quarter end date reference from 'September 30' to 'March 31'
- Newer filing (2026-05-05) added 'Global Conflicts' section describing impact of Middle East hostilities on energy markets and supply chains
- Removed:
- Older filing (2025-11-03) contained 'deductibility of goodwill' and 'projected impacts of tariff and trade policy changes and uncertainty' in forward-looking statements list; these were removed in newer filing
- Older filing (2025-11-03) referenced '2024 Annual Report' and prior quarterly reports for March 31, 2025 and June 30, 2025; newer filing references only '2025 Annual Report'
- Older filing (2025-11-03) contained extensive 'Changes in Tariff and Trade Policies' subsection with detailed discussion; this section is not present in newer filing (text truncated)
- Older filing (2025-11-03) listed 'Point-of-care electrolytes and blood gas analyzers for the human medical diagnostics sector' as separate product line; newer filing consolidated this into 'manufacture and sell human medical point-of-care diagnostic products'
- Older filing (2025-11-03) provided detailed Operating Segments description naming 'OPTI Medical' and explaining foreign currency treatment; newer filing uses simplified 'Other operating segment' description
- Reworded:
- Human medical business description changed from 'provide human medical point-of-care diagnostics' (older) to 'manufacture and sell human medical point-of-care diagnostic products' (newer)
- Practice management systems description changed from 'Practice management and diagnostic imaging systems' (older) to 'Practice management systems, software and diagnostic imaging systems' (newer) - added 'software'
- Water products description changed from 'Products that test water for certain microbiological contaminants' (older) to 'Products that test water for certain microbiological contaminants' (newer) - no substantive change
- Operating segments description structure simplified in newer filing; older filing provided more detailed explanation of each segment's function
- Notes:
- Older filing text is truncated at end of 'Changes in Tariff and Trade Policies' section, limiting full comparison of that section
- Two filings compare different fiscal periods (March 31, 2026 vs. September 30, 2025), which explains some content differences beyond pure wording changes
- Some differences reflect substantive business restructuring (e.g., segment description changes) versus simple rewording
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($1M) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 1 sell ($1M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-04. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IDXX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 20 matched disclosures for IDXX from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding IDXX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 13,019,285
- Reported value $6,853,872,411
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IDXX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IDXX had 1,917,016 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
IDXX had 2.43% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.77 days to cover at the same settlement.
- Reported short interest (shares) 1,917,016
- Short interest (% of shares outstanding) 2.43%
- Prior settlement (shares) 2,092,080
- Reported change -8.37%
- Days to cover (reported) 3.77
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Zoetis (ZTS)
- Heska (owned by Mars)
- Thermo Fisher Scientific (TMO)
- Siemens Healthineers (SMMNY)
- VCA (owned by Mars)
- Covetrus
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IDXX vs…
Idexx Laboratories is found in…
IDXX ranks in…
IDXX shows up in…
Frequently asked questions
What does Idexx Laboratories (IDXX) do?
IDEXX Laboratories is a global leader in pet healthcare innovation, providing diagnostic and software solutions for veterinary practitioners. The company offers a broad range of diagnostic instruments, test kits, and reference laboratory services, alongside practice management software, to help veterinarians provide advanced medical care and improve practice efficiency.
What sector is Idexx Laboratories (IDXX) in?
Idexx Laboratories (IDXX) is classified in the Health Care sector. Its industry is veterinary diagnostics. It trades on NASDAQ.
Who are Idexx Laboratories's (IDXX) competitors?
Notable peers of Idexx Laboratories (IDXX) include Zoetis, Heska (owned by Mars), Thermo Fisher Scientific, Siemens Healthineers and VCA (owned by Mars). This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in IDXX?
Yes — we hold 20 matched STOCK Act disclosures for IDXX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Idexx Laboratories (IDXX) overbought or oversold right now?
Idexx Laboratories (IDXX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IDXX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.